$USAQ from their news: “The acquisition of the AllergiEnd® assets also provides USAQ the opportunity to more fully integrate and leverage the product portfolio across our marketing platform, customer relationships and cost structure, which we expect will facilitate improvement in our margin profile over time. Finally, our pipeline of organic growth opportunities remains active and focused on expanding our distribution channels and product portfolio,” concluded Grogan
(0)
(0)